Pharmacotherapy for weight loss: the cardiovascular effects of the old and new agents
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Pharmacotherapy for weight loss: the cardiovascular effects of the old and new agents
Authors
Keywords
-
Journal
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
Volume 39, Issue 5, Pages 475-484
Publisher
Wiley
Online
2014-06-13
DOI
10.1111/jcpt.12177
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Incretin-based therapies: can we achieve glycemic control and cardioprotection?
- (2013) Franca S Angeli et al. JOURNAL OF ENDOCRINOLOGY
- Drug Treatment of Obesity in Cardiovascular Disease
- (2012) Marietta Charakida et al. American Journal of Cardiovascular Drugs
- Randomized Placebo-Controlled Clinical Trial of Lorcaserin for Weight Loss in Type 2 Diabetes Mellitus: The BLOOM-DM Study
- (2012) Patrick M. O'Neil et al. Obesity
- Anti-Obesity Drugs: A Review about Their Effects and Safety
- (2012) Jun Goo Kang et al. Diabetes & Metabolism Journal
- Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study
- (2011) W Timothy Garvey et al. AMERICAN JOURNAL OF CLINICAL NUTRITION
- Benefits of Modest Weight Loss in Improving Cardiovascular Risk Factors in Overweight and Obese Individuals With Type 2 Diabetes
- (2011) R. R. Wing et al. DIABETES CARE
- A One-Year Randomized Trial of Lorcaserin for Weight Loss in Obese and Overweight Adults: The BLOSSOM Trial
- (2011) Meredith C. Fidler et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial
- (2011) Kishore M Gadde et al. LANCET
- Controlled-Release Phentermine/Topiramate in Severely Obese Adults: A Randomized Controlled Trial (EQUIP)
- (2011) David B. Allison et al. Obesity
- Cardiovascular Risk-Benefit Profile of Sibutramine
- (2010) A.J. Scheen American Journal of Cardiovascular Drugs
- How ephedrine escaped regulation in the United States: A historical review of misuse and associated policy
- (2010) Joseph Palamar HEALTH POLICY
- Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
- (2010) Frank L Greenway et al. LANCET
- Multicenter, Placebo-Controlled Trial of Lorcaserin for Weight Management
- (2010) Steven R. Smith et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese Subjects
- (2010) W. Philip T. James et al. NEW ENGLAND JOURNAL OF MEDICINE
- Serotonergic drugs and valvular heart disease
- (2009) Richard B Rothman et al. Expert Opinion On Drug Safety
- Parallel Functional Activity Profiling Reveals Valvulopathogens Are Potent 5-Hydroxytryptamine2B Receptor Agonists: Implications for Drug Safety Assessment
- (2009) X.-P. Huang et al. MOLECULAR PHARMACOLOGY
- Pulmonary hypertension: therapeutic targets within the serotonin system
- (2008) Y Dempsie et al. BRITISH JOURNAL OF PHARMACOLOGY
- Serotonin and Angiotensin Receptors in Cardiac Fibroblasts Coregulate Adrenergic-Dependent Cardiac Hypertrophy
- (2008) Fabrice Jaffré et al. CIRCULATION RESEARCH
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More